TARA — Protara Therapeutics Share News
0.000.00%
Last trade - 00:00Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses
Brief: Protara Therapeutics Q1 EPS USD -0.31
Protara Q4 net loss widens on higher R&D spend
U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials
U.S. STOCKS ON THE MOVE-Domino's Pizza, FactSet, IBM
U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet
Protara tumbles as cancer drug data falls short of investor expectations
Brief: TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Brief: Protara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Protara Therapeutics Announces Dosing Of First Patient In Phase 3 Registrational Thrive-3 Trial
Brief: Protara Therapeutics Gets FDA Breakthrough
U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Biotech co Protara slides on $75 mln share sale
Brief: Protara Prices Public Offering Of 13.04 Million Shares At $5.75 Each